The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
Fiche publication
Date publication
mai 2016
Journal
Expert opinion on drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Pitt B, Rossignol P
Lien Pubmed
Résumé
Mineralocorticoid receptor antagonists (MRAs) have been accorded a class 1 indication for patients with chronic heart failure and a reduced left ventricular ejection fraction (HFREF) in both European and American guidelines. Uptake, however, has been less than optimal largely due to concerns about their safety, in particular the risk of hyperkalemia and renal dysfunction.
Mots clés
Heart Failure, drug therapy, Hospitalization, Humans, Hyperkalemia, chemically induced, Kidney Diseases, chemically induced, Mineralocorticoid Receptor Antagonists, adverse effects, Patient Selection, Practice Guidelines as Topic, Ventricular Dysfunction, Left, drug therapy
Référence
Expert Opin Drug Saf. 2016 May;15(5):659-65